• Policy
• Severe AD treatments unlikely to be reimb this year
• by Lee, Tak-Sun Oct 21, 2022 05:48am

• Policy
• Epclusa, a hepatitis C tx, costs 117,030 won
• by Kim, Jung-Ju Oct 21, 2022 05:48am

• Company
• Tumor-agnostic Vitrakvi lands in Big 5 tertiary hospitals
• by Eo, Yun-Ho Oct 21, 2022 05:47am

• Policy
• The head of the MFDS actively agrees with the opinion
• by Lee, Hye-Kyung Oct 21, 2022 05:47am

• Company
• Celltrion develops anticancer drugs using ADC platform
• by Oct 21, 2022 05:47am

• Policy
• Xtandi’s use expanded... reimbursement standard changed
• by Lee, Tak-Sun Oct 20, 2022 06:02am

• Opinion
• [Reporter’s View] LG Chem’s global two-track strategy
• by Oct 20, 2022 06:02am

• Company
• LG Chem acquires US pharma company for KRW 800 billion
• by Chon, Seung-Hyun Oct 19, 2022 05:49am

• Policy
• All targets for the benefit reassessment will be negotiated
• by Lee, Tak-Sun Oct 19, 2022 05:48am

• Company
• Novo Nordisk appoints Sasha Semienchuk as new GM
• by Eo, Yun-Ho Oct 19, 2022 05:48am